This segment sells various agricultural products such as seeds and herbicides. The stock is trading with P/E ratio of 9.46 right now. Meanwhile, Bayer's crop science business reported sales of 4.7 billion euros, which decreased slightly (by 0.2%) compared with the year-ago period. First, there's the crop science segment, which Bayer claims is the "world's leading agriculture enterprise." Jun. Its crop science business sells products that are indispensable for the healthy growth of agricultural products, and its pharmaceutical and consumer health businesses offer medical products to the public, showing that Bayer is eager to take on these challenges and profit from them.
Finally, there's Bayer's consumer health division, which sells over-the-counter (OTC) medical products, including such famous brands as Aleve, Alka-Seltzer, and Claritin.Bayer's earnings before interest and taxes (EBIT) improved significantly year over year. Bayer also expects its core earnings per share (EPS) for fiscal 2020 to grow to between 7 euros and 7.20 euros (the company's core EPS for the fiscal year 2019 was 6.40 euros). Bayer is a classic “special situation” stock whose near-term performance will depend less on operating profits than on developments in the Roundup courtroom drama. One stock to keep an eye on is Bayer (BAYRY). Those are certainly attractive valuation metrics, but does Bayer have the tools to perform much better than it did over the past five years?Bayer's other segments did not perform as well, however.
The pharmaceutical segment was arguably the best performer. Hence the company's vision: "health for all, hunger for none. Over the past five years, shares of Bayer (OTC: BAYRY) are down by 65%. The company argues that the world's population is both increasing and aging. For its pharmaceutical segment, the company projected sales growth between 3% and 4% compared with fiscal 2019, as well as growth of 4% in crop science and between 2% and 3% in consumer health. BAYRY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The consumer health division recorded total sales of 1.3 billion euros, a measly 0.5% year-over-year increase. This compares unfavorably to the S&P 500 , which is up by 18% over the same period.
Second, there's the company's pharmaceutical business. However, it is essential to note that these projections do not include potential adverse effects caused by the ongoing COVID-19 pandemic: "The forecast does not yet include an estimate of the potential impact of the coronavirus outbreak," the company said in a statement.Bayer operates through three segments. Bayer's pharmaceutical sales for the fourth quarter totaled 4.7 million euros, a 9.1% increase compared with the year-ago period.Bayer is betting on two worldwide trends to help its business grow in the future. The company argues that the world's population is both increasing and aging. The consumer health division recorded total sales of 1.3 billion euros, a measly 0.5% year-over-year increase. Returns as of 07/30/2020.However, the past is the past, and Bayer could outpace the broader market from here on out -- which would make the company a buy, given that it's currently trading at just 7 times future earnings and its forward price-to-earnings growth (PEG) ratio is just 0.1. "This performance was spearheaded by products including Xarelto, an anticoagulant with 1.2 billion euros in sales for the quarter, a 15.6% increase compared with the fourth quarter of 2018.
"Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.This performance was spearheaded by products including Xarelto, an anticoagulant with 1.2 billion euros in sales for the quarter, a 15.6% increase compared with the fourth quarter of 2018.